Clinical Edge Journal Scan

Meta-analysis demonstrates potential of probiotics in reducing atopic dermatitis disease severity


 

Key clinical point: The use of probiotic supplementation reduced disease severity in adult patients with atopic dermatitis (AD).

Major finding: Probiotic supplementation vs placebo led to a significant reduction in the Scoring AD index (mean difference βˆ’7.90; 95% CI βˆ’7.25 toβˆ’6.92), but no significant improvements in skin severity and itch severity.

Study details: Findings are from a meta-analysis of six randomized controlled trials including 241 adults with AD, of which 128 received probiotics and 113 received placebo.

Disclosures: This study was funded by a grant from Universitas Airlangga, Indonesia. The authors declared no conflicts of interest.

Source: Umborowati MA et al. The role of probiotics in the treatment of adult atopic dermatitis: a meta-analysis of randomized controlled trials. J Health Popul Nutr. 2022;41:37 (Aug 17). Doi: 10.1186/s41043-022-00318-6

Recommended Reading

Optimizing Narrowband UVB Phototherapy: Is It More Challenging for Your Older Patients?
MDedge Dermatology
Dupilumab shows good drug survival in moderate-to-severe atopic dermatitis
MDedge Dermatology
Meta-analysis finds no increased VTE risk in AD patients receiving JAK inhibitors
MDedge Dermatology
Brepocitinib shows potential against mild-to-moderate atopic dermatitis in phase 2 trial
MDedge Dermatology
Rapid itch reduction with ruxolitinib in mild-to-moderate atopic dermatitis
MDedge Dermatology
EHA cream shows promise in children with mild-to-moderate atopic dermatitis
MDedge Dermatology
Moderate-to-severe atopic dermatitis: Astegolimab fails to reduce disease severity in phase 2 trial
MDedge Dermatology
Early initiation of emollient reduces risk for atopic dermatitis in high risk infants
MDedge Dermatology
Pediatric atopic dermatitis and neuropsychiatric disorders: What is the link?
MDedge Dermatology
Real-world characteristics of patients with moderate-to-severe atopic dermatitis receiving dupilumab
MDedge Dermatology